for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UPDATE 1-Bristol, Pfizer to seek apixaban approval

* To submit application in first half of 2010

* Shares of Bristol, Pfizer edge up in late trading

LOS ANGELES, Dec 4 (Reuters) - Drugmakers Bristol-Myers Squibb Co BMY.N and Pfizer PFE.N plan to seek in the first half of 2010 regulatory approval in Europe for apixaban, a drug meant to prevent and treat clots in blood vessels, the companies said on Friday.

The drugmakers said in a statement that they will seek approval for the drug’s use for patients who have had orthopedic surgery and will support their application with results from two clinical trials.

New drugs to prevent dangerous blood clots promise to shake up the market but pharmaceutical companies face an uphill fight on price. [ID:nL1530044]

Bristol-Myers and Pfizer teamed up in 2007 to develop and commercialize apixaban, which is taken orally.

Other companies developing or selling new blood-clotting drugs include AstraZeneca AZN.L, Eli Lilly LLY.N, BayerBAYGn.DE and Johnson & Johnson JNJ.N.

Shares of Bristol-Myers were up nearly 1 percent at $25.30 each in after-hours trading after closing down 0.08 percent at $25.14 on Friday on the New York Stock Exchange.

Shares of Pfizer were trading one penny up in after-hours after closing slightly down 0.8 percent at $18.49 on Friday on the New York Stock Exchange. (Reporting by Laura Isensee; editing by Carol Bishopric) ((laura.isensee@thomsonreuters.com; Los Angeles Bureau +213 380 2014))

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up